All In Biotech

Drug Trial Radar · NCT07444541

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety and Efficacy of ANO31905 for Injection in Combination With Chemotherapy as the First-line Treatment for Patients With CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Aug 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Anova Innovation LimitedIndustry
Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.

Conditions

  • Pancreatic Cancer

Interventions

  • ANO31905Drug

    ANO31905 will be administered as an IV infusion

  • AG [gemcitabine+nab-paclitaxel]Drug

    125 mg/m\^2 of nab-paclitaxel, intravenous infusion, D1/D8/D15 per cycle; 1000 mg/m\^2 of gemcitabine, intravenous infusion, D1/D8/D15 per cycle until PD, intolerable toxicity or other discontinuation criteria specified in the protocol (whichever occurs first).

  • mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]Drug

    Oxaliplatin, 85 mg/m\^2; irinotecan (non-liposome injection), 180 mg/m\^2; leucovorin, 400 mg/m\^2; and fluorouracil, 2400 mg/m\^2 given as a 46-hour continuous infusion, on D1/D15 per cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT) (Phase Ib).Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Objective response rate (ORR) assessed by the investigator according to Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1) (Phase Ⅱ)Time frame: Up to 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Site 01002

    Los Angeles, California · Recruiting

  • Site 01009

    Plantation, Florida · Recruiting

  • Site 01005

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.